MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Net Income
-$873,467
EPS
-$1.81
Unit: Dollar
Income Statement
2025-09-30
2025-06-30
Research and development
61,826
116,383
General and administrative
833,304
849,182
Total operating expenses
895,130
965,565
Loss before other income (expense)
-895,130
-965,565
Interest income, net
21,663
7,740
Loss from continuing operations
-873,467
-957,825
Net loss
-873,467
-957,825
Basic EPS
-1.81
-0.45
Diluted EPS
-1.81
-0.45
Basic Average Shares
481,587
2,122,872
Diluted Average Shares
481,587
2,122,872
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Net loss-$873,467 Loss from continuingoperations-$873,467 Interest income, net$21,663 Loss before otherincome (expense)-$895,130 Total operatingexpenses$895,130 General andadministrative$833,304 Research and development$61,826

Salarius Pharmaceuticals, Inc. (SLRX)

Salarius Pharmaceuticals, Inc. (SLRX)